HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium

Authors:	Rathi N. Pillai MD Madhusmita Behera PhD Lynne D. Berry PhD Mike R. Rossi PhD Mark G. Kris MD Bruce E. Johnson MD Paul A. Bunn MD Suresh S. Ramalingam MD Fadlo R. Khuri MD

Affiliation:	1. Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia;2. Vanderbilt Center for Quantitative Sciences, Vanderbilt‐Ingram Cancer Center, Nashville, Tennessee;3. Division of Cancer Biology, Department of Radiation Oncology, Emory University, Atlanta, Georgia;4. Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York;5. Clinical Research, Dana‐Farber Cancer Institute, Boston, Massachusetts;6. Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado

Abstract:

Keywords:	human epidermal growth factor receptor 2 (HER2) lung adenocarcinoma Lung Cancer Mutation Consortium (LCMC) multiplexed sequencing targeted therapy